Protara Therapeutics, Inc. (TARA) posted a Q4 2025 loss of $0.37 per share, narrower than the $0.48 per share loss reported in the year-ago quarter. The clinical-stage biopharmaceutical company continues to advance its lead program TARA-002, an investigational cell therapy currently in Phase II clinical trials for non-muscle invasive bladder cancer and lymphatic malformations.
The company focuses on developing transformative therapies for the treatment of cancer and rare diseases. The wider-than-expected loss reflects ongoing clinical development expenses as Protara progresses its pipeline programs.
A detailed analysis of Protara Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Protara Therapeutics, Inc. (TARA) Reports Narrower Loss for Q4 first appeared on Alphastreet.
